ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug Monitoring of
            <i>ALK+</i>
            Non–Small Cell Lung Cancer?

Cathleen June Park; Alexandria T.M. Lee; Sai-Hong Ignatius Ou

doi:10.1200/jco-24-02514

ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug Monitoring of <i>ALK+</i> Non–Small Cell Lung Cancer?

C Cathleen June Park (University of California Irvine School of Medicine, Department of Medicine, Division of Hematology-Oncology, Orange/Irvine, CA) A Alexandria T.M. Lee (University of California Irvine School of Medicine, Department of Medicine, Division of Hematology-Oncology, Orange/Irvine, CA) S Sai-Hong Ignatius Ou (University of California, Irvine School of Medicine, Orange)

View Original

APA MLA Chicago BibTeX RIS

Article Details

Journal Journal of Clinical Oncology

Volume / Issue Vol. 43, Issue 6

Published February 20, 2025

Pages 625-628

DOI 10.1200/jco-24-02514

ISSN 0732-183X

Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (3)

C

Cathleen June Park

University of California Irvine School of Medicine, Department of Medicine, Division of Hematology-Oncology, Orange/Irvine, CA

A

Alexandria T.M. Lee

University of California Irvine School of Medicine, Department of Medicine, Division of Hematology-Oncology, Orange/Irvine, CA

S

Sai-Hong Ignatius Ou

University of California, Irvine School of Medicine, Orange

ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug Monitoring of <i>ALK+</i> Non–Small Cell Lung Cancer?

Article Details

Journal Info

Authors (3)

Related Articles from this Journal

Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)

Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer